Engineered t cells take on Hard-to-Treat myeloma
NCT ID NCT03602612
First seen Mar 03, 2026 · Last updated Jun 14, 2026 · Updated 16 times
Summary
This early-phase trial tests the safety of giving people with multiple myeloma their own genetically modified T cells. The cells are reprogrammed to better recognize and attack myeloma cells. The study enrolls 35 adults whose cancer has not responded to standard therapies. Participants receive chemotherapy before the cell infusion and are monitored closely for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.